The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has
been spreading rampantly. The global scientific community has responded rapidly to …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Summary SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19, making
them a focus of vaccine design. A safety concern regarding SARS-CoV-2 antibodies is …

Most of SARS-CoV-2 neutralizing antibodies (nAbs) targeted the receptor binding domain
(RBD) of the SARS-CoV-2 spike (S) protein. However, mutations at RBD sequences found in …

Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …